Biohaven strikes a deal to take TYK2 drugs in a new direction

Can a promising new way of treating common immune diseases like psoriasis also work for disorders of the brain and nervous system?

Biohaven, a biotechnology company rebooted after a 2022 sale to Pfizer, aims to find out, announcing Wednesday a deal to license a so-called TYK2 inhibitor from Chinese drugmaker Hangzhou Highlightll Pharmaceutical.